OX1R Inhibitors
3 drugsAbout OX1R
The orexin 1 receptor (OX1R) is a G protein-coupled receptor involved in regulating sleep-wake cycles and arousal. It is activated by the neuropeptides orexin A and orexin B, influencing neuronal activity and downstream signaling pathways.
OX1R has emerged as a significant pharmaceutical target, though currently there is no genetic evidence directly linking it to specific diseases. The clinical success of OX1R-modulating drugs underscores its therapeutic potential for sleep disorders.
Three FDA-approved drugs, DAYVIGO, QUVIVIQ, and BELSOMRA, target OX1R, all of which are small molecules. These drugs, developed by EISAI INC, IDORSIA, and Merck respectively, are approved for sleep disorders.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Delayed Sleep Phase Syndrome with only 2 trials.
Top Drugs
Three companies, EISAI INC, IDORSIA, and Merck, have approved drugs targeting OX1R.
The limited number of players indicates a moderately concentrated market with potential entry barriers.
Drug Modality Landscape
Modalities
Routes of Administration
OX1R is amenable to small molecule drugs, with oral options available for convenient dosing.
The exclusive use of small molecules suggests an opportunity for alternative modalities like antibodies or peptides.
Clinical Trials 141 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 39 | 37 | 0 | 2 | 100% |
| Phase 2 | 42 | 17 | 6 | 19 | 74% |
| Phase 3 | 22 | 19 | 0 | 3 | 100% |
| Phase 4 | 38 | 20 | 5 | 13 | 80% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved OX1R drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting OX1R. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2014 - 2022)
The first OX1R-targeting drug was approved in 2014, with the most recent approval in 2022.
The 9-year span between approvals suggests a potentially maturing market with slowing innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 104 clinical trials targeting OX1R.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities